Connect with us

Uncategorized

Major Run on RLFTF (Relief Therapeutics Holding) On Successful ZYESAMI 2b/3 Trial Results as Submission of Phase 3 data & EUA Looms Large

Published

on

RLFTF has been moving northbound in a hurry after its partner NeuroRx, Inc. announced the Phase 2b/3 trial* of ZYESAMI™ (aviptadil, previously RLF-100™) for the treatment of Respiratory Failure in critically ill patients with Covid-19 has demonstrated multidimensional benefit around its prespecified primary endpoint of Recovery from Respiratory Failure with discharge from hospital and ICU (without relapse) by day 28 in patients with critical Covid-19 who were treated with High Flow Nasal Oxygen. NeuroRx has signed an agreement to complete a business combination with Big Rock Partners Acquisition Corporation (NASDAQ:BRPA). ZYESAMI™ represents a huge step forward in the fight against covid 19 and EU seems likely now and could be the catalyst that finally ignites RLFTF and propels the stock into a whole new level. Investors are looking for a break over $0.95 highs seen in August for confirmation of the next leg up.  

ZYESAMI™ a synthetic vasoactive intestinal peptide (VIP) is the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. While drugs such as dexamethasone, Remdesivir and Monoclonal antibodies/convalescent plasma have been approved for fighting COVID, these drugs have minimal efficacy, are expensive to produce and difficult to transport. ZYESAMI™ is simple to manufacture and cheap to produce at scale. Another popular synthetic vasoactive intestinal peptide (VIP) is insulin. ZYESAMI™ represents a significant breakthrough in the fight against covid 19 and means there is now an effective therapy for patients in the ICU improving oxygenation, and getting patients out of the hospital faster. Rapid adoption in ICUs nationwide can be anticipated as well as peer reviewed publication of results in the Lancet and other journals. NeuroRx is planning to file for Emergency Use Authorization in this patient population if positive results continue to be demonstrated at day-60 endpoint in line with FDA’s new guidance. Based on the favorable results, one can reasonably conclude the submission of phase 3 data has already occurred to the FDA in anticipation of possible EUA. 

Relief Therapeutics Holding AG (SIX: RLF; OTCQB: RLFTF) focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100™ (aviptadil) is being investigated in two placebo-controlled U.S. late-stage clinical trials in respiratory deficiency due to COVID-19. Relief holds a patent issued in the United States and various other countries covering potential formulations of RLF-100™. The Company’s partner NeuroRx draws upon more than 100 years of collective drug development experience from senior executives of AstraZeneca, Eli Lilly, Novartis, Pfizer, and PPD. In addition to its work on ZYESAMI™, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials.  

ZYESAMI™ a synthetic vasoactive intestinal peptide (VIP), is the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100TM under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM. VIP is shown to block Coronavirus replication in the ATII cell, block cytokine synthesis, block viral-induced cell death (cytopathy), and upregulate surfactant production. To our knowledge, other than ZYESAMI™, no currently proposed treatments for Covid-19 specifically target these vulnerable Type II cells. Recent laboratory findings suggest that VIP directly interferes with the spike protein complex of the SARS-CoV-2 virus. 

On February 23 NeuroRx, Inc. announced the Phase 2b/3 trial* of ZYESAMI™ (aviptadil, previously RLF-100™) for the treatment of Respiratory Failure in critically ill patients with Covid-19 has demonstrated multidimensional benefit around its prespecified primary endpoint of Recovery from Respiratory Failure with discharge from hospital and ICU (without relapse) by day 28 in patients with critical Covid-19 who were treated with High Flow Nasal Oxygen. Although not envisioned at the start of the clinical trial, High Flow Nasal Oxygen has become the predominant form of treatment in Covid-19 respiratory failure, with mechanical ventilation reserved for those whose blood oxygen levels cannot be maintained on this less invasive modality. The trial was conducted at 10 U.S. hospitals under the direction of NeuroRx in collaboration with RELIEF THERAPEUTICS Holding AG (SIX: RLF; OTCQB: RLFTF). NeuroRx has signed an agreement to complete a business combination with Big Rock Partners Acquisition Corporation (NASDAQ:BRPA). 

Investor sentiment in RLFTF is very high:

To Find out the inside Scoop on Relief Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RLFTFThe clinical trial was originally approved as a 28-day study at FDA’s direction. In December, NeuroRx added a 60-day endpoint based on the recognition that the traditional 28-day endpoint adopted in the 1990s for trials in Acute Respiratory Distress Syndrome is not appropriate for critically ill patients with Covid-19, who are frequently maintained in the ICU with advanced technologies well beyond this time point. NeuroRx and other clinical trial sponsors alerted FDA to this trend and yesterday the FDA published formal guidance† changing the required time for measuring the prespecified endpoint of “alive and free of respiratory failure” in critically ill patients to 60 days.  Interim data are being reported because they were unblinded as per the original protocol and the last patient in the trial reached day 60 yesterday. Therefore, study conduct cannot be adversely influenced by release of these interim findings. 

At 28 days, patients treated with ZYESAMI™ demonstrate 35% higher likelihood of recovery from respiratory failure with continued survival compared to patients treated with placebo (Hazard Ratio 1.53; P=.08). In tertiary care hospitals, ZYESAMI-treated patients were 46% more likely to recover and return home before day 28 (Hazard Ratio controlling for age and severity 1.84; P=.058). Should these trends continue through day 60, they have the potential to reach statistical significance. At day 28, a highly significant 10-day difference in median time to recovery and hospital discharge has emerged in ZYESAMI-treated patients compared to those treated with placebo (P<.006). 

Should the above trends continue through day 60, NeuroRx anticipates filing a request for Emergency Use Authorization in this population of critically ill patients (i.e. those on High Flow Nasal Oxygen) who have exhausted all currently approved treatments. FDA decisions implement a benefit/risk framework. NeuroRx previously announced the high degree of safety observed with use of ZYESAMI.  This safety has continued to be documented in the more than 300 additional patients treated under the Expanded Access Protocol and in patients who have filed requests under the federal Right to Try act. 

The study’s principal investigators, Dushyantha Jayaweera, M.D., FACP (University of Miami), Professors J. Georges Youssef, M.D. (Houston Methodist Hospital), and Richard Lee, M.D. (University of California, Irvine), commented, “We are excited to report that ZYESAMI demonstrates a highly significant reduction in time to recovery compared to patients treated with placebo in those treated with High Flow Nasal Oxygen, together with increased likelihood of recovery and excellent safety. We look forward to learning whether this benefit can also be shown for patients treated with other stages of Covid-19 with inhaled forms of ZYESAMI. We look forward to working with the sponsor to secure emergency use authorization for ZYESAMI in this population of patients.”  

https://twitter.com/TonyFauci2/status/1364294025675755522

For more on Relief Therepuetics Subscribe Right Now!

RLFTF has been moving northbound in a hurry after its partner NeuroRx, Inc. announced the Phase 2b/3 trial* of ZYESAMI™ (aviptadil, previously RLF-100™) for the treatment of Respiratory Failure in critically ill patients with Covid-19 has demonstrated multidimensional benefit around its prespecified primary endpoint of Recovery from Respiratory Failure with discharge from hospital and ICU (without relapse) by day 28 in patients with critical Covid-19 who were treated with High Flow Nasal Oxygen. NeuroRx has signed an agreement to complete a business combination with Big Rock Partners Acquisition Corporation (NASDAQ:BRPA). ZYESAMI™ represents a huge step forward in the fight against covid 19 and EU seems likely now and could be the catalyst that finally ignites RLFTF and propels the stock into a whole new level. Investors are looking for a break over $0.95 highs seen in August for confirmation of the next leg up.   ZYESAMI™ a synthetic vasoactive intestinal peptide (VIP) is the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. While drugs such as dexamethasone, Remdesivir and Monoclonal antibodies/convalescent plasma have been approved for fighting COVID, these drugs have minimal efficacy, are expensive to produce and difficult to transport. ZYESAMI™ is simple to manufacture and cheap to produce at scale. Another popular synthetic vasoactive intestinal peptide (VIP) is insulin. ZYESAMI™ represents a significant breakthrough in the fight against covid 19 and means there is now an effective therapy for patients in the ICU improving oxygenation, and getting patients out of the hospital faster. Rapid adoption in ICUs nationwide can be anticipated as well as peer reviewed publication of results in the Lancet and other journals. NeuroRx is planning to file for Emergency Use Authorization in this patient population if positive results continue to be demonstrated at day-60 endpoint in line with FDA’s new guidance. Based on the favorable results, one can reasonably conclude the submission of phase 3 data has already occurred to the FDA in anticipation of possible EUA. We will be updating on Relief on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with Relief.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in Relief either long or short and we have not been compensated for this article.

Uncategorized

Meta Materials Inc (OTCMKTS: MMTLP) Short Squeeze is ON as FINRA Approves Corporate Action, DTC Notifying Brokers; Effective Date is Tuesday December 13

Published

on

Meta Materials Inc (OTCMKTS: MMTLP) is rocketing up the charts after FINRA approved the corporate action and its now displaying on the daily list with the effective date of Tuesday, December 13. DTC will now send the corporate action notice to brokers who will begin closing out short positions; the MMTLP short squeeze is now ON. According to FINRA MMTLP shareholders with settled positions as of December 12, the Record Date will receive 1 share of Next Bridge Hydrocarbons, Inc. for every 1 share of MMTLP held on the Pay Date of December 14. Purchases of MMTLP executed after December 8 will not receive the distribution. To receive the dividend once must own or buy the stock tomorrow or Monday and hold through the effective date. MMTLP shares will be canceled effective Tuesday, December 12 at 4pm. Expect a press release from META premarket tomorrow explaining everything in detail. 

Our thoughts on MMTLP and what happened: 

As everyone knows by now MMTLP was halted and will not resume trading again. If you go on YouTube there are dozens of videos now saying that FINRA is corrupt and working with the hedge funds to screw the little guy and that what happened to MMTLP is “unprecedented” and nothing like this happens on the bulletin boards.    

This of course is not what happened FINRA is not corrupt and they are not working with anyone. FINRA rightfully halted the stock to protect shareholders who would have bought MMTLP after the 8th because anyone buying after the 8th did not get the Nextbridge shares and would have been buying an empty placeholder. Everyone who was invested in MMTLP will now be shareholders in Nextbridge Hydrocarbons, a private Company.

As for the short squeeze, we believed just like everyone else, MMTLP was skyrocketing up the charts, dozens of YouTube channels, stock twits, reddit everywhere else all saying the same. Youtube Bird lady rollerpigions saying there was millions of MMTLP shares short and then the Torchlight CEO John Brda appearing on multiple live streams with Bird Lady agreeing with everything she was saying and going as far as saying that “everything Bird Lady was saying was right over the bullseye” this gave her an air of legitimacy, we believed her.

We have now listened to the logic of the youtubers and one thing they all seem to miss is that MMTLP was not trading like a stock that had this enormous short position stuck in it during the last week. If an enormous short position of 10s of millions of shares had to cover in days, they would have been covering a long time ago. The last day that MMTLP traded last Thursday it lost almost half its value, relentless selling. Investors saw the writing on the wall, there was no short squeeze happening here and they were selling.  We have come to the conclusion that there never was a short position on MMTLP and in the coming days when they balance the books, we believe that’s exactly what they will show. FINRA was is just doing its job. 

________________________________________________________ 

MMTLP had a wild trading day on Tuesday falling to a low of $5.04 as the shorts executed one final massive short attack before FINRA posted MMTLP on the daily list and the stock went parabolic skyrocketing to highs of $9.70 per share and closing at $8.25 up 16% on the day on 5 million shares traded. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Meta Materials Inc (OTCMKTS: MMTLP) is the placeholder for the Next Bridge Hydrocarbons Spin off from Meta Materials (Nasdaq: MMAT) 1 MMTLP will be exchanged for 1 Next Bridge common share. 

Next Bridge Hydrocarbons is developing its Orogrande Project, in the Permian Basin in West Texas, USA. The Orogrande Project has potential for multi-stack pay zone, totaling up to 800 feet thick, with geologic and reservoir similarities to the Midland Basin. . The Permian Basin is a prolific oil and gas producing region and has produced 29 billion barrels of oil since output began in 1921 and despite that rich history, the Permian Basin’s best days could be ahead. Due to new advanced extraction techniques oil companies have figured out how to unlock the oil and gas trapped within the basins unique geology encompassing several stacked layers of hydrocarbon-bearing rock formations. Some of the biggest oil operators in the Country have a long history in the Permian Basin including Chevron, ExxonMobil, Occidental Petroleum, and Apache and many, many others. 

Image

https://twitter.com/MMATNEWS/status/1600221162168279040

To Find out more on MMTLP Subscribe to Microcapdaily.com Right Now by entering your Email address below 

On Reddit, in the subreddit r/MMAT u/Free_Bid6752 posted: FINRA UPDATED 

AriaTisa replied: “The stock MMTLP will stop trading after closing on December 12th. If you are short, you have to close your position by then. If you want NB stock, you must buy MMTLP by end of the 8th and hold. Selling your shares on the 9th or 12 means the person who bought it will get NB stock but you have to transfer it to them.” 

NotRichorFamous replied: “Next bridge is the private company that MMTLP is turning into. It’s expected that it will either get bought out by a big oil company or the land will be sold to a big oil company and stock holders will get a cash dividend at that time.” 

Standard-Letter1130 replied: “To close the estimated (confirmed by John Brda there was that many, not sure how many of that original still need shares to cover) 80M TRCH (trapped) positions. A short would require 1 MMTLP & 0.5 MMAT shares. They will run up together, just not entirely sure by how much, but looks to be around a 15%-20% ratio. I.e. MMTLP goes up to $100, MMAT would be around $15-$20 based on the price ratio since S1 Approval.” 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we have not been compensated for this article. We have never spoken to anyone at MMLTP, we believed what everyone was saying including the tweets from John Brda and RollerPigeons on youtube because she regularly spoke with John Brda and NextBridge/Meta management. Now I think it was all a lie, I dont think there ever was all these millions of shares short. We got caught up in the hype and we apologize to anyone that lost money. To be clear, we did not trade this stock, just as we dont trade any stocks posted on this website, we just wrote about it thats it.

Continue Reading

Uncategorized

Meta Materials Inc (OTCMKTS: MMTLP) Enormous Short Position in Trouble as Next Bridge Hydrocarbons Set to Stop Trading (George Palikaras & John Brda on Corporate Action)

Published

on

Meta Materials Inc (OTCMKTS: MMTLP) has an enormous week ahead as the short squeeze enters its final trading days and the massive estimated 80 to 100 million short position must now cover. The excitement on MMTLP is palpable with numbers like $60 per share or $80 per share at the height of the short squeeze being thrown around and many investors vowing not to sell MMTLP for less than $100 per share. John Brda and George Palikaras have gotten busy on twitter as we wait for the corporate action to be processed by FINRA and sent to brokers by DTC. While shorts time to cover is running out, they continue to play short and distort, borrowing another 291,000 shares on Friday alone, and launching 3 separate short attacks throughout the day.  

Our thoughts on MMTLP and what happened: 

As everyone knows by now MMTLP was halted and will not resume trading again. If you go on YouTube there are dozens of videos now saying that FINRA is corrupt and working with the hedge funds to screw the little guy and that what happened to MMTLP is “unprecedented” and nothing like this happens on the bulletin boards.    

This of course is not what happened FINRA is not corrupt and they are not working with anyone. FINRA rightfully halted the stock to protect shareholders who would have bought MMTLP after the 8th because anyone buying after the 8th did not get the Nextbridge shares and would have been buying an empty placeholder. Everyone who was invested in MMTLP will now be shareholders in Nextbridge Hydrocarbons, a private Company.

As for the short squeeze, we believed just like everyone else, MMTLP was skyrocketing up the charts, dozens of YouTube channels, stock twits, reddit everywhere else all saying the same. Youtube Bird lady rollerpigions saying there was millions of MMTLP shares short and then the Torchlight CEO John Brda appearing on multiple live streams with Bird Lady agreeing with everything she was saying and going as far as saying that “everything Bird Lady was saying was right over the bullseye” this gave her an air of legitimacy, we believed her.

We have now listened to the logic of the youtubers and one thing they all seem to miss is that MMTLP was not trading like a stock that had this enormous short position stuck in it during the last week. If an enormous short position of 10s of millions of shares had to cover in days, they would have been covering a long time ago. The last day that MMTLP traded last Thursday it lost almost half its value, relentless selling. Investors saw the writing on the wall, there was no short squeeze happening here and they were selling.  We have come to the conclusion that there never was a short position on MMTLP and in the coming days when they balance the books, we believe that’s exactly what they will show. FINRA was is just doing its job. 

 

Meta Materials Inc (OTCMKTS: MMTLP) is the placeholder for the Next Bridge Hydrocarbons Spin off from Meta Materials. One MMTLP (Series A Preferred share) will be exchanged into one Next Bridge common share once the spinoff is completed.

Next Bridge Hydrocarbons is exclusively developing its Orogrande Basin asset, the Orogrande Project, located in the Permian Basin in West Texas. The Orogrande Project has shown to have potential for multi-stack pay zone, totaling 600 to 800 feet thick, with geologic and reservoir similarities to the Midland Basin. 

The Permian Basin, also called West Texas Basin, is a large sedimentary basin in western Texas and southeastern New Mexico, U.S., noted for its rich petroleum, natural gas, and potassium deposits. The Permian Basin is one of the most prolific oil and gas producing regions in the world. The Basin produced a prodigious 29 billion barrels of oil since output began in 1921. However, despite that rich production history, its best days could lie ahead. Thanks to new extraction techniques oil companies have finally figured out how to unlock the oil and gas trapped within its unique geology encompassing several stacked layers of hydrocarbon-bearing rock formations. Permian Basin operators are driving oil and gas production to all time new highs. Many of the biggest oil operators in the country have a long history in the Permian including Occidental Petroleum, Chevron, ExxonMobil, and Apache to name just a few. 

To Find out the inside Scoop on MMTLP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

MMTLP

Metamaterial News tweeted on Thursday that there are “Over 150 comments on @FINRA page/post regarding MMTLP (Their Twitter Engagement up 500%+ ) Over 200 mentions of $MMTLP and @FINRA from peoples post. Over 20 confirmed calls to FINRA regarding MMTLP. We are using are voice as investors now let’s see action. On Saturday he retweeted:

https://twitter.com/AShortSqueeze/status/1599021715161419776

  For More on MMTLP Subscribe Right Now!

John Brda h John Brda has continued tweeting on Saturday concerning the corporate action tweeting: Friend spoke with @FINRA examiner.  He was told that they are acutely aware of the $MMTLP issue, but could deny corporate action or request change to S1 using rule 6490..Last bullet pt. in 6490 reads, can be denied if: there is significant uncertainty in the settlement and clearance process for the security. Telling if denied for this reason since @FINRA listed $MMTLP with no issuer knowledge and with fraud info. “While it seems unlikely that FINRA would approve the record and distribution dates and then not process the Corporate Action John Brda continues to investigate tweeting later on Saturday: “I hear there is a bit of confusion going on. @FINRA has not notified anyone of anything.  We are continuing to move forward and will push this through.”  We will update on MMTLP as soon as anything new happens so make sure you are subscribed to Microcapdaily by entering your email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we have not been compensated for this article. We have never spoken to anyone at MMLTP, we believed what everyone was saying including the tweets from John Brda and RollerPigeons on youtube because she regularly spoke with John Brda and NextBridge/Meta management. Now I think it was all a lie, I dont think there ever was all these millions of shares short. We got caught up in the hype and we apologize to anyone that lost money. To be clear, we did not trade this stock, just as we dont trade any stocks posted on this website, we just wrote about it thats it.

Continue Reading

Featured

Renewable Innovations, Inc. (RI) RM; the Rise of Nestbuilder.com Corp (OTCMKTS: NBLD)

Published

on

Nestbuilder.com Corp (OTCMKTS: NBLD) is moving quickly up the charts after the Company announced a reverse merger with Renewable Innovations, Inc. (RI), whereby Renewable Innovations will be the surviving Company. Renewable Innovations is a big deal; the Company is an emerging leader in clean, hydrogen fuel cell energy systems and has a deal in place with General Motors to supply the military with clean energy. Renewable Innovations plans to uplist to the Nasdaq as soon as it is eligible. 

Reverse Mergers can be more explosive than biotech’s when the incoming Company has real value but is undiscovered to investors and many RM stocks, we have covered on this website have gone from pennies to dollars. One recent RM runners that stand out is HRBR which went from a few cents (where we first wrote about it) to $3 plus. NBLD is debt free 100% fully reporting OTCQB and a valuable reverse merger candidate. NBLD hit a high of $0.93 on Thursday and closed at $0.80 up 2,200% on the day on 1.9 million shares traded. 

NBLD Friday 4PM Close Update: NBLD rocketed up another 210% on Friday to close at $2.50 per share. The stock hit highs of $3.75 on about $5 million in dollar volume. As we reported NBLD is under heavy accumulation after the Company announced a reverse merger with Renewable Innovations, Inc. (RI), whereby Renewable Innovations will be the surviving Company. Renewable Innovations is a big deal; the Company is an emerging leader in clean, hydrogen fuel cell energy systems and has a deal in place with General Motors to supply the military with clean energy. Renewable Innovations plans to uplist to the Nasdaq as soon as it is eligible. We will be updating on NBLD as soon as anything new happens so make sure you are subscribed to Microcapdaily by entering your email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Nestbuilder.com Corp (OTCMKTS: NBLD) was incorporated in the State of Nevada on January 10, 2017 as a wholly owned subsidiary of RealBiz Media Group, Inc., a Delaware corporation On July 31, 2018. Prior business was servicing large and small broker accounts in the North America Real Estate Market. The Company had the ability to produce over 15,000 videos per day. They also owned the website LoseTheAgent.com. 

Renewable Innovations, Inc. (RI), goal is to accelerate the growth and opportunities within the renewable economy. The Company’s team of industry leaders brings extensive experience and connections across the Renewable, Hydrogen, and Alternative Energy sectors. Along with its partners, investors, and clients, RI is making major technological advancements with products and solutions to lead the world into a new and exciting carbon-free future. Renewable Innovations, advanced power integration, applications, and solutions are focused on creating a new Hydrogen-powered energy economy including Hydrogen Fuel Cell (HFC) scalable backup and primary power systems, Mobile and transportable HFC-powered EV Rapid Charge systems for the Electric Vehicle market, Advanced Hydrogen transport and refueling vehicles and Greenhouse Grids to power communities. 

Immediately prior to the Merger, there were 6,090,580 shares of our Common Stock issued and outstanding and warrants outstanding to acquire up to an aggregate of 10,135,000 shares of our Common Stock. As a result of the Merger, we issued to the shareholders of Renewable Innovations an aggregate of 2,155,684 shares of our Series A Convertible Preferred Stock, par value $0.0001 per share, each share of which is convertible into 100 shares of our Common Stock, which represents a 93% ownership interest based on our fully-diluted capitalization immediately following the Merger. As a result of the foregoing transactions, we underwent a change of control on December 1, 2022. 

In connection with the closing of the Merger, the following changes to the Board occurred on December 1, 2022 (the “Closing Date”), which will result in a change of a majority of the members of the Board: Thomas M. Grbelja and William McLeod resigned as members of the Board, effective on the Closing Date; Robert L. Mount was appointed as a member of the Board, effective on the Closing Date; Lynn Barney was appointed as a member of the Board, effective 10 days after the mailing of this Information Statement to our shareholders; and Alex Aliksanyan resigned as a member of the Board, effective 10 days after the mailing of this Information Statement to our shareholders. 

Currently General Motors is supplying HYDROTEC fuel cell power cubes to Renewable Innovations of Lindon, Utah to build the Mobile Power Generator. GM will combine its fuel cell hardware and software with Renewable Innovations’ power integration and management systems to create a generator that can provide fast-charging capability for EVs without having to expand the grid or install permanent charging assets in places where there’s only a temporary need for power.  

Multiple development projects involving the MPG are already in process, including a demonstration of the technology as a mobile charging station for EVs funded in part by the Michigan Economic Development Corporation and the U.S. Army Combat Capabilities Development Command Ground Vehicle Systems Center. This version of the MPG is expected to first be demonstrated in mid-2022. 

The California Energy Commission is funding a separate demonstration program of four additional MPGs through its Mobile Renewable Backup Generation systems program to show how hydrogen-based mobile power can help offset the loss of energy during the planned power shutoffs used to mitigate wildfires throughout the state. This demonstration is being led by the Electric Power Research Institute, the preeminent independent, non-profit energy research and development organization, collaborating with stakeholders like GM and Renewable Innovations to ensure the public has safe, reliable, affordable and equitable access to hydrogen-generated electricity.

To Find out the inside Scoop on NBLD Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

NBLD

 

In addition to mobile EV charging, GM and Renewable Innovations have collaborated on the EMPOWER rapid charger. Intended to help retail fuel stations add more affordable DC fast charging capability, the EMPOWER rapid charger will help deploy necessary fast charging without significant investment in nonrecoverable electrical infrastructure upgrades, like larger feed wires, transformers and potentially new substations. 

Palletized Mobile Power Generator System – GM designed a separate, palletized version of the MPG which is now being evaluated by U.S. Army Combat Capabilities Development Command Ground Vehicle Systems Center (GVSC).  GVSC is also exploring how this version of the MPG can power heavy-duty military equipment and camps. This prototype is equivalent in size to a 60-kW generator and produces nearly 70 percent more power than traditional diesel generators. This MPG variant also contains features not typically found on diesel generators, like battery backup and output regulation.   

GM will produce HYDROTEC power cubes at its Fuel Cell Systems Manufacturing joint venture with Honda in Brownstown, Michigan. Renewable Innovations will produce the trailer-based MPG and the larger, modular EMPOWER rapid charger at their facilities in the Salt Lake City metro area. 

Renewable Innovations shareholders will retain ninety-three percent (93%) of the publicly traded entity, which has been renamed Renewable Innovations, Inc. The Company intends to leverage its breakthrough hydrogen fuel cell technology, bringing grid independent, clean, renewable solutions for power generation and sustainability to the market. Plans include expansion into retail power distribution, especially along the US highway system through organic growth and acquisitions. Currently, the company is in production on orders for government and private company projects. Renewable Innovation’s integration technology allows for rapid charging of a vehicle in under 20 minutes, offering a significant time savings over current EV charging portals. Since the hydrogen-fueled systems require no grid infrastructure, they can be provisioned anywhere that rapid, carbon-free power is needed.  

Renewable Innovations, Inc. will continue to trade on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the symbol “NBLD” until such time as FINRA approves the name and symbol change. The Company intends to file for a listing on NASDAQ as soon as it is eligible. 

For More on NBLD Subscribe Right Now!

NBLD is rocketing up the charts after announcing the reverse merger with Renewable Innovations, Inc. (RI), an emerging leader in clean, hydrogen fuel cell energy systems that has deals in place with General Motors to supply the military with clean energy. Renewable Innovations plans to uplist to the Nasdaq as soon as it is eligible. Renewable Innovations new campus features 170,000 sq ft of office, R&D, and manufacturing space. We have covered many reverse mergers on this website including HRBR for pennies per share which went on to run to $3 on the Air Wisconsin Reverse merger. Not since HRBR have we seen a bulletin boards RM with as much potential as this Renewable Innovations. We will be updating on NBLD when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in NBLD either long or short and we have not been compensated for this article

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.